Abstract

The evolution of the tumor microenvironment (TME) is a cancer-dependent and dynamic process. The TME is often a complex ecosystem with immunosuppressive and tumor-promoting functions. Conventional chemotherapy and radiotherapy, primarily focus on inducing tumor apoptosis and hijacking tumor growth, whereas the tumor-protective microenvironment cannot be altered or destructed. Thus, tumor cells can quickly escape from extraneous attack and develop therapeutic resistance, eventually leading to treatment failure. As an Epstein Barr virus (EBV)-associated malignancy, nasopharyngeal carcinoma (NPC) is frequently infiltrated with varied stromal cells, making its microenvironment a highly heterogeneous and suppressive harbor protecting tumor cells from drug penetration, immune attack, and facilitating tumor development. In the last decade, targeted therapy and immunotherapy have emerged as promising options to treat advanced, metastatic, recurrent, and resistant NPC, but lack of understanding of the TME had hindered the therapeutic development and optimization. Single-cell sequencing of NPC-infiltrating cells has recently deciphered stromal composition and functional dynamics in the TME and non-malignant counterpart. In this review, we aim to depict the stromal landscape of NPC in detail based on recent advances, and propose various microenvironment-based approaches for precision therapy.

Highlights

  • nasopharyngeal carcinoma (NPC) is a unique type of cancer in terms of its geographical distribution, differentiation grade and microenvironmental landscape

  • Few studies have reported that T cell and myeloid-derived cells are the predominant stromal subtypes in the NPC microenvironment based on hematoxylin and eosin (H&E) staining, immunohistological (IHC) staining and flow cytometry [10,11,12]

  • We aim to address the stromal landscape in NPC based on recent advances, and subsequently propose a variety of approaches to enhance therapeutic response and patient prognosis via targeting the immunosuppressive and tumor-promoting microenvironment

Read more

Summary

INTRODUCTION

NPC is a unique type of cancer in terms of its geographical distribution, differentiation grade and microenvironmental landscape. The response rate for pembrolizumab in NPC (phase I, 25.9%) is significantly higher than in non-small-cell lung cancer (phase I, 19.4%), hepatocellular carcinoma (phase III, 18.4%) and gastroesophageal cancer (phase II, 11.6%), synergistically targeting more highly expressed receptors in NPC-infiltrating exhausted T cells might enhance the anti-tumor immunity of PD-1 monotherapy [53,54,55]. Accumulating evidence has suggested that the enrichment of Tregs in the NPC microenvironment is caused by tumormediated recruitment, where CCR4+ and CCR6+ resting Treg are migrated from peripheral blood and activated into a suppressive phenotype via tumor-secreted CXCL10, CXCL16, CCL20, and CD70 binding [50, 71, 72] Targeting these Tregattractive chemokines produced by NPC cells might alleviate the infiltration of Tregs in the TME and sustain CD8+ cytotoxicity. It remains necessary to evaluate the prognostic value of NK-specific signatures and investigate the mechanism so that we can have a better understanding of the role of NK cells in the NPC microenvironment that might facilitate therapeutic development in the future

TARGETING B CELLS TO ENHANCE RESPONSE TO IMMUNOTHERAPY
EXTRACELLULAR MATRIX
DISCUSSION
Tumor cells Tumor cells
Available drugs or approaches
Findings
AUTHOR CONTRIBUTIONS
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call